As of Friday close, Outlook Therapeutics Inc.’s (NASDAQ:OTLK) stock was down -$0.01, moving down -0.99 percent to $1.00. The average number of shares traded per day over the past five days has been 1,259,240 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0100 fall in that time frame. In the last twenty days, the average volume was 740,455, while in the previous 50 days, it was 650,838.
Since last month, OTLK stock retreated -13.79%. Shares of the company fell to $0.9900 on 03/17/23, the lowest level in the past month. A 52-week high of $2.12 was reached on 01/17/23 after having rallying from a 52-week low of $0.68. Since the beginning of this year, OTLK’s stock price has dropped by -7.41% or -$0.0800, and marked a new high 6 times. However, the stock has declined by -52.83% since its 52-week high.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
OTLK stock investors should be aware that Outlook Therapeutics Inc. (OTLK) stock had its last reported insider trading activity 57 days ago on Jan 20. Evanson Jeff, the Chief Commercial Officer of the company, disposed of 267,000 shares for $1.11 on Jan 20. It resulted in a $296,370 divestment by the insider. Evanson Jeff sold 103,255 shares at an average price of $1.22 on Jan 19. The insider now owns 1,012,975 shares following the transaction. On Jan 18, Chief Commercial Officer Evanson Jeff sold 33,738 shares at $1.25 apiece. The transaction was valued at $42,172.
In the three months ended December 30, Outlook Therapeutics Inc.’s quick ratio stood at 4.10, while its current ratio was 4.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending December 30 was 2.01, and the total debt-to-equity ratio was 2.01. Based on annual data, OTLK earned $63.07 million in gross profit.
In Outlook Therapeutics Inc.’s quarter-end financial report for December 30, it reported total debt of $31.82 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Outlook Therapeutics Inc. to report -$0.05 quarterly earnings, the actual figure was -$0.08 per share. During the quarter, the company generated -$15.68 million in EBITDA. The liabilities of Outlook Therapeutics Inc. were 46.93 million at the end of its most recent quarter ended December 30, and its total debt was $31.85 million. The value of shareholders’ equity is $256.67 million.
This quick technical analysis looks at Outlook Therapeutics Inc.’s (OTLK) price momentum. With a historical volatility rate of 38.95%, the RSI 9-day stood at 33.23% on 17 March.
With respect to its five-day moving average, the current Outlook Therapeutics Inc. price is down by -0.99% percent or -$0.0100. At present, OTLK shares trade -10.71% below its 20-day simple moving average and -15.25% percent below its 100-day simple moving average. However, the stock is currently trading approximately -5.66% below its SMA50 and -13.04% below its SMA200.
Stochastic coefficient K was 7.52% and Stochastic coefficient D was 10.97%, while ATR was 0.0660. Given the Stochastic reading of 5.56% for the 14-day period, the RSI (14) reading has been calculated as 37.46%. As of today, the MACD Oscillator reading stands at -0.0367, while the 14-day reading stands at -0.0533.
Cantor Fitzgerald launched its rating on Outlook Therapeutics Inc. (NASDAQ: OTLK) to an Overweight in a note to investors on February 06, 2023. Outlook Therapeutics Inc. (OTLK) has been rated Buy by analysts. According to 0 brokerage firms, OTLK is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Outlook Therapeutics Inc. stock as buy, with 5 recommending it as overweight.
With a median target price of $7.00, the current consensus forecast for the stock is $4.00 – $10.00. Based on these forecasts, analysts predict Outlook Therapeutics Inc. (OTLK) will achieve an average price target of $6.80.